



## Supplementary Materials:



**Figure S1. The fingerprint of LJZT and its compositions.** All lyophilized hot water extracts of LJZ decoction and each herb were weighed about 0.5 g and dissolved in 50 mL 50% MeOH. The samples were soaked for 2 hours at room temperature, ultrasonic extracted for 60 min (300 W, 40 kHz), and then filtrated through a 0.22  $\mu\text{m}$  membrane before loading on UPLC. UPLC was performed using an Agilent 1200 Infinity Series (Santa Clara, CA, USA) equipped with Zorbax RRHP Eclipse Plus C18 column (2.1x50 mm, 1.8  $\mu\text{m}$ ). The mobile phase included A (0.1% formic acid in H<sub>2</sub>O) and B (0.1% formic acid in acetonitrile). The gradient elution program was B channel 10-10% (0-1 min), 10-30% (1-3.5 min), 30-50% (3.5-7 min), 50-10% (7-7.1 min), and 10-10% (7-10 min). Flow rate was 0.3 mL/min. The UV detector wavelength was 254 nm. Profile a, b, c, d, e, f, g, h, and i respectively represented LJZT, Gan Cao, Chen Pi, Bai Zhu, Sheng Jiang, Fu Ling, Ban Xia, Ren Shen, and Da Zao. Peak 1, 2, 3, and 4 respectively indicated liquiritin, naringin, hesperidin, and glycyrrhizic acid. According to the Pharmacopoeia of the People's Republic of China 2010 (Volume I, page 898), hesperidin was use a requiring reference index of Xiang-Sha-Liujuun Wan which contains two more herbs (Rhizome of *Rosa banksiae* R. Br. and fruit of *Amomum villosum* Lour.) than LJZT has.



**Figure S2. LJZT failed to prevent cisplatin-induced toxicity in two cancer cell lines.** (A) human colon adenocarcinoma grade II (HT29) cells and (B) human non-small cell lung carcinoma cells (H460) with or without treating with LJZT in different dosages for 1 h and with or without treatment with cisplatin for another 24 h. Cells were then subjected to a neutral red assay. Viability is expressed as a percentage of controls. Data is presented as the mean  $\pm$  SD. \* $p < 0.05$ , compared to controls ( $n = 3-6$ ).